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The microgranular variant (M3v) of acute promyelocytic leukemia (APL) is rare, and the diag-
nosis can be delayed due to variability in how this condition presents. M3v blasts often have
folded nuclei, but unlike traditional APL blasts, they often possess faint granules without Auer
rods. In addition, microgranular APL often presents with an elevated or normal white blood cell
count in contrast with the leukopenia seen in traditional APL. In APL, delayed diagnosis can lead
to early death from disseminated intravascular coagulation (DIC), which is the main cause of
mortality in an otherwise treatable, and often curable, leukemia. We describe a 19-year-old
male with microgranular APL who presented with leukopenia and many blasts resembling
non-APL AML blasts with an unexpected immunophenotypic pattern. He was treated for DIC
and initiated on all-trans-retinoic acid and arsenic trioxide; he achieved complete molecular
remission after induction therapy. Suspicion for APL should always remain high in the presence
of clinical manifestations of the disease in order that appropriate treatment can be initiated
rapidly to prevent early death.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).arlotte, NC
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Figure 1 Peripheral blood. (A) The majority of circulating
blasts lacked obvious nuclear folding. (B) Typical acute-
promyelocytic-leukemia blasts were infrequently seen with
lacy folded nucleus and scant blue cytoplasm. These cells
possessed some eosinophilic granules, but no Auer rods.
2 M.H. McDonnell et al.Introduction
The microgranular variant (M3v) of acute promyelocytic leu-
kemia (APL) is similar to classical APL in that it is character-
ized by the t(15;17) chromosomal abnormality. However,
there are multiple features that set it apart. As opposed
to the prominent granules typically seen in APL, M3v blasts
possess a faint scattering of granules in the cytoplasm, and
they often lack Auer rods [1]. However, as is the case in tra-
ditional APL, they often have folded nuclei [2]. Microgranu-
lar APL is rare, given that APL comprises approximately
5–10% of all acute myeloid leukemia (AML) cases, with
the M3v accounting for only 10–25% of all APL [3]. Given
the rarity of M3v, this disease can be misdiagnosed, as it
can easily be confused with myelomonocytic or monocytic
AML [4].
With the introduction of anthracyclines and subsequently
all-trans retinoic acid (ATRA) for the treatment of APL, this
form of leukemia has become curable in the majority of
cases. The incorporation of arsenic trioxide (ATO) into APL
treatment regimens has further increased remission rates
and cure rates in APL, while decreasing toxicity [5].
Lo-Coco et al. [5] noted that 100% of low- and
intermediate-risk APL patients treated with ATRA–ATO
achieved complete remission, with 97% of patients
achieving 2-year event-free survival.
The greatest cause of treatment failure in APL is early
death, which affects an estimated 10–30% of patients [6].
More than half of early-death cases are ascribed to
hemorrhagic-related complications of disseminated
intravascular coagulation (DIC) [7,8]. Rapid initiation of
ATRA therapy results in a significant decrease in early death
[8]. Multiple factors correlate with delays in diagnosis and
treatment, including admissions to facilities with little
experience in acute leukemia and unusual presentations of
APL, sometimes with the absence of DIC [6,9].
Misdiagnosis can occur with M3v due to its atypical clin-
ical presentation and pathological characteristics. Tradi-
tional APL presents with leukopenia, whereas M3v is
generally associated with a normal to elevated white blood
cell (WBC) count [10]. Given the risk of misdiagnosis or
delayed diagnosis of APL, flow cytometry has been widely
adopted as a rapid method for diagnosis. APL blasts fre-
quently express the myeloid antigens CD13, CD33, CD64,
and CD117, and often lack expression of CD34 and human
leukocyte antigen–D related (HLA–DR) [11–14].
In this report, we describe a patient who presented with
microgranular APL with atypical clinical, morphological,
and immunophenotypic features.
Case report
A previously healthy 19-year-old male developed epistaxis.
After 3 days of persistent bleeding, he presented to a local
emergency department and was treated with oxymetazoline
nasal spray and right naris packing. He was found to be
thrombocytopenic and coagulopathic and, therefore, was
transferred to our institution for management. On presenta-
tion, WBC was 2.6 K/lL with 46% blasts, hemoglobin was
9.3 g/dL, and platelet count was 32 K/lL. Prothrombin timePlease cite this article in press as: McDonnell MH et al., Microgranular a
sual immunophenotype ..., Hematol Oncol Stem Cell Ther (2016), http://(PT) was 14.1 s, fibrinogen 99 mg/dL, D-dimer 8.32 lg/dL,
haptoglobin 6 mg/dL, and lactate dehydrogenase (LDH)
316 IU/L. The patient was treated for DIC with cryoprecipi-
tate infusions and platelet transfusions.
Peripheral blood smear showed normochromic, normo-
cytic red blood cells with no schistocytes, microsphero-
cytes, red-blood-cell fragments, or basophilic stippling. In
addition, the circulating blasts were characterized by lacy
chromatin with scant blue cytoplasm. Some had eosinophilic
granules, but no Auer rods were seen. The occasional blast
had a ‘‘folded’’ or cleft nucleus, but the majority did not
(Figure 1).
Flow cytometry on the peripheral blood revealed a blast
population uniformly positive for CD2, moderate-bright
CD33, CD34, CD38, and CD117. There was heterogeneous
expression of CD13, CD56, and dim CD123. There was also
limited and heterogeneous expression of dim HLA–DR.
These cells were negative for surface CD3, CD11c, CD14,
and CD64. On account of the patient’s coagulopathy, ATRA
was initiated as empiric therapy for APL.
Bone-marrow aspirate and biopsy (Figure 2) were per-
formed. The core biopsy exhibited 100% cellularity with a
leukemic cell infiltrate throughout, and the touch imprint
showed 69.5% blasts that lacked conspicuous granulation
or Auer rods. Fluorescent in situ hybridization revealed
the presence of t(15;17)(q24;q21) in 72% of the cells. Thecute promyelocytic leukemia presenting with leukopenia and an unu-
dx.doi.org/10.1016/j.hemonc.2015.12.004
Figure 2 Bone-marrow biopsy and aspirate. (A and B) There was nearly 100% cellularity in the core biopsy with leukemic cell
infiltrate throughout. (C) On the aspirate smear, there were blast cells similar in appearance to the cells observed in the peripheral
blood. These cells had limited to moderate cytoplasm with rounded to polymorphous nuclei. (D) On the touch imprint, there was an
admixture of lymphocytes and immature cells, some with lobulated nuclei and limited cytoplasm.
Microgranular acute promyelocytic leukemia 3presence of this translocation was confirmed by conven-
tional cytogenetics. ATRA was continued, and ATO was ini-
tiated. Polymerase chain reaction revealed the presence
of the feline McDonough sarcoma (FMS)-like tyrosine kinase
3 (FLT3) internal-tandem-duplication mutation.
The patient developed a nonproductive cough 3 days into
therapy; chest X-ray was consistent with interstitial pneu-
monitis. WBC rose to a peak of 26.8 K/lL, and the patient
developed acute renal failure. The patient was initiated
on dexamethasone for differentiation syndrome; ATRA and
ATO were held until resolution of respiratory symptoms
and renal failure. Treatment was subsequently resumed.
The patient’s peripheral blood promyelocytic locus–
retinoic acid receptor alpha (PML–RARA) polymerase chain
reaction on day 30 of induction therapy revealed no molec-
ular evidence of disease. The patient underwent bone-
marrow aspirate and biopsy following the completion of
induction, revealing complete morphological, immunophe-
notypic, cytogenetic, and molecular remission.Discussion
M3v can offer a diagnostic challenge, particularly when it
presents atypically. The incidence of M3v presenting with
leukopenia is unknown, and to our knowledge, there are
no previous reports that specifically address M3v in the set-
ting of leukopenia. In an analysis of three APL trials, thePlease cite this article in press as: McDonnell MH et al., Microgranular a
sual immunophenotype ..., Hematol Oncol Stem Cell Ther (2016), http://WBC range among 155 M3v patients was 0.6–550 K/lL with
a median of 15.8 K/lL, implying that it is unusual, but not
impossible, for M3v patients to present with leukopenia [7].
While there is no universal APL phenotype, this condition
is usually CD13, CD33, CD64, and CD117 positive, and CD34,
HLA–DR, and CD2 negative [11–14]. Specifically, CD34 is
expressed in 15–21% of APL cases with HLA–DR expressed
in only approximately 3–9% of cases [4,12,13,15,16]. M3v
has a more heterogeneous immunophenotype than tradi-
tional APL, expressing CD34 almost universally and express-
ing HLA–DR, CD56, and CD2 occasionally [11,13,17–20].
A number of the aforementioned markers associated
with M3v have been associated with poorer outcomes. CD2
positivity correlates with leukocytosis, shorter complete
remission duration, and a trend for shorter overall survival
[13]. CD56 expression carries a poor prognosis with an
increased risk of relapse following ATRA–anthracycline
therapy [18,21,22]. Lastly, CD34 positivity has been shown
in most, but not all, studies to carry a worse prognosis than
CD34 negativity [9,23–25].
It is curious whether CD2, CD34, and CD56 expressions
have an intrinsic, biologic effect on the increased risk of
early death, or whether the diagnostic challenge that these
features can pose is responsible for high rates of early
death. In the largest study addressing outcomes in M3v,
Tallman et al. [7] found that M3v carried a decreased over-
all survival compared to classical APL; however, when
adjusting for WBC count, the difference disappeared. Oncute promyelocytic leukemia presenting with leukopenia and an unu-
dx.doi.org/10.1016/j.hemonc.2015.12.004
4 M.H. McDonnell et al.the basis of this finding, one could hypothesize that the
adverse prognosis of M3v may be attributed entirely to the
leukocytosis that accompanies it and/or the diagnostic chal-
lenge presented by M3v. Of note, this study did not directly
evaluate immunophenotype as a variable in determining
prognosis.
APL is a highly curable disease, but when death occurs, it
is most often from early death, which can occur due to
delayed diagnosis. Therefore, it is important to identify
atypical presentations of APL. Our patient’s presentation
highlights the significant clinical, morphological, and
immunophenotypic heterogeneity with which APL can pre-
sent. Moreover, this case illustrates that microgranular APL
can present with a low WBC count and with leukemia cells
that can resemble non-APL AML blasts. In addition, this case
demonstrates that the immunophenotypic pattern in M3v
can be different from the typical APL pattern. Until cytoge-
netic and/or molecular information is available, medical
decision making must rely upon the clinical manifestations
of the disease—such as coagulopathy in a patient with abnor-
mal blood counts—rather than the absence of typical morpho-
logical and immunophenotypic features of the disease.
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